To date, no clinical trials have investigated targeted inhibition of S100A8/A9 in cardiovascular diseases, underscoring the need to assess the safety and efficacy of S100A8/A9 inhibitors in phase 2 trials. Here, IGKV1D-22 is linked to cardiovascular disorder.